ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
Read Article
ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs
A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (
Read Article
ICYMI: Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Read Article
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
HLA-B27 Testing in Practice
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined.
Read Article
Increasing costs of biologics. X-sectional study of 76 781 psoriasis pts on biologics (TNFi, IL12/23, IL-17i, IL-23i) saw annual treatment cost increase from $21 236 in 2007 to $47 125 in 2021. AVG cost could have been 44% lower if lowest-cost Rx in same class was used https://t.co/IOaK75zsgg
Dr. John Cush @RheumNow( View Tweet )
Simple Measures are Effective in Knee Osteoarthritis
EurekAlert!
Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of the First People’s Hospital of Neijiang, China.
Knee
Read Article
Rheumatoid arthritis incidence has risen to 17.9 million people globally -13.2% increase from 1990-2021. Fewer people are dying from RA, but disability-adjusted life Yrs have doubled. high sociodemographic index bore the heaviest burden. Smoking control policies is forecasted to https://t.co/YmWcinVdmE
Dr. John Cush @RheumNow( View Tweet )
Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV
Dr. John Cush @RheumNow( View Tweet )
Nurse-Led Treat-to-Target Clinics
EurekAlert!
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
Read Article
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases (RMDs). Across multiple sessions and studies, delegates are presenting compelling https://t.co/nmdyJYQV0B
Dr. John Cush @RheumNow( View Tweet )
Why do Rheumatologists shift to private practice? Are there gender based differences?
A survey of 100+ European rheumatologists
Female 🚺 rheumatologists:
Leave hospital earlier
At a lower hierarchical level
Reasons for leaving:
nightshifts
unfair promotion decisions
Aurelie Najm @AurelieRheumo( View Tweet )
Social disparities in rheumatology @RheumNow #EULAR2025
~70% of outcomes are determined by Social determinants of health
Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy
Bella Mehta @bella_mehta( View Tweet )
@RheumNow Achieving health equity is the goal
1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX
Bella Mehta @bella_mehta( View Tweet )
How much of the health outcomes are related to social determinants?
🔺️Up to 75%!
Disaster Medicine Session
Social disparities and impact on outcomes
Dr Kate Webb
#EULAR2025
@RheumNow https://t.co/0Ahbf79Nbx
Nelly ZIADE 🍀 @Nellziade( View Tweet )
What do we know about disparities in #SLE
- worse in women
- worse in non white populations
- have lower quality of care in vulnerable populations
- have worse outcomes in vulnerable populations
#EULAR2025 @rheumnow
Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65
Bella Mehta @bella_mehta( View Tweet )
#Lupus is one of the biggest social discriminators
🔺️Higher prevalence in Women
🔺️Higher prevalence in Non-Whites
🔺️More catastrophic manifestations in low socioeconomic groups
Disaster Medicine Session
Social disparities and impact on outcomes
#EULAR2025
@RheumNow https://t.co/mewR9NzXHt
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Delay hurts.
Dx delay in axial SpA costs UK £3.1 billion annually.
Avg time to dx = 8.5 yrs
Avg dx cost = £187k/person
Fixing delay could save £167k/person.
Early Dx isn’t just better care—it’s economic policy.
#EULAR2025 @RheumNow
#AxialSpA #RMD https://t.co/eYEQ2rp94m
Jiha Lee @JihaRheum( View Tweet )
Social Determinants of Health in SLE
EurekAlert!
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research
Read Article
Premature death in RA still exists, and varies according to race/ethnicity demographic groups
Nationwide US CDC's MCoD database analysis
-Mortality rates
11x higher American Indians
3x higher Black or African American people
-Median age at death with RA
9-10 years younger https://t.co/FTRWPk7Wz0
Aurelie Najm @AurelieRheumo( View Tweet )
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
Access inequity across Europe is real.
New #RheumaFacts data show major gaps in RMD care:
🔹 Full tsDMARD access in just 4% of countries
🔹 Self-referral possible in 57%
🔹 Rheum physio reimbursed in 63%
🔹 Psych care? Only 30%.
Abstract#OP0025
@RheumNow #EULAR2025
Jiha Lee @JihaRheum( View Tweet )
Debuting Fishbowl sessions at #EULAR2025 🔄💊
Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed!
@RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK
Jiha Lee @JihaRheum( View Tweet )
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA patients may be instrumental in
MTX Fails Knee OA (6.6.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read ArticleRecent Blogs
The advantage to patient care without the crutch of an EHR. What do you do?
Read Post
